Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
22.59
35.01
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sichuan Kelun Pharmaceutical Co Ltd
Total Equity
Sichuan Kelun Pharmaceutical Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
|
Total Equity
ÂĄ22.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Equity
ÂĄ25.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Equity
ÂĄ13.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Equity
ÂĄ42.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Equity
ÂĄ39.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Equity
ÂĄ151.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Sichuan Kelun Pharmaceutical Co Ltd
Glance View
Sichuan Kelun Pharmaceutical Co., Ltd., established in 1997 and headquartered in Chengdu, China, has rapidly emerged as a formidable player in the pharmaceutical industry. The company specializes in the research, development, and production of a diverse range of pharmaceuticals, including innovative drugs, generic medications, and active pharmaceutical ingredients (APIs). Kelun has built a strong reputation for its commitment to quality and safety, evidenced by its compliance with international regulatory standards and certifications such as FDA and EMA approvals. With a robust portfolio that spans key therapeutic areas like oncology, cardiovascular diseases, and infectious diseases, Kelun not only caters to the growing domestic demand but is also expanding its footprint in the global market, making it an appealing prospect for investors seeking growth in the health sector. As the pharmaceutical landscape in China evolves, fueled by increasing healthcare expenditures and an aging population, Kelun is strategically positioned to capitalize on these trends. The company's significant investments in research and development underscore its ambition to innovate and introduce new therapies that meet pressing healthcare needs. Furthermore, strategic collaborations with international partners enhance its technological capabilities and market reach. With strong financial metrics that reflect steady revenue growth and profitability, Kelun stands poised to leverage its operational expertise and strategic initiatives for sustained expansion. For investors, Sichuan Kelun Pharmaceutical represents an attractive opportunity to tap into the burgeoning pharmaceutical market led by a company marked by quality, innovation, and a clear vision for future growth.
See Also
What is Sichuan Kelun Pharmaceutical Co Ltd's Total Equity?
Total Equity
22.3B
CNY
Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Total Equity amounts to 22.3B CNY.
What is Sichuan Kelun Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
8%
Over the last year, the Total Equity growth was 18%. The average annual Total Equity growth rates for Sichuan Kelun Pharmaceutical Co Ltd have been 18% over the past three years , 11% over the past five years , and 8% over the past ten years .